Recordati S.p.A. - SWOT, Strategy and Corporate Finance Report - new company profile report

London 10/29/2012 11:26 AM GMT (TransWorldNews)

Recordati S.p.A. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

- Detailed information on Recordati S.p.A. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Recordati S.p.A. in the form of a SWOT analysis
- An in-depth view of the business model of Recordati S.p.A. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Recordati S.p.A.
- Intelligence on Recordati S.p.A.nv's mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Recordati S.p.A., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Recordati is a mid-sized European pharmaceutical company marketing ethical pharmaceuticals, most of which have been in-licensed for development and marketing within specific European markets. The company markets its products in more than 100 countries, primarily in the EU. The company is headquartered in Milan, Italy and employed 2,800 employees as of December 2010. The company recorded revenues of E728.1 million ($966 million*) during the financial year (FY) ended December 2010, a decrease of 2.6% over FY2009. The operating profit of the company was E154.8 million ($205.4 million*) during FY2010, a decrease of 4.6% over FY2009. The net profit was E108.6 million ($144 million*) in FY2010, a decrease of 1.8% over FY2009. *Calculated using the constant conversion rate E1 = $1.3267 for the financial year ended December 31, 2010.
Reasons to Purchase:

- Gain understanding of Recordati S.p.A. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Recordati S.p.A. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Recordati S.p.A.'s business structure, strategy and prospects



Click for Report details:Recordati S.p.A. - SWOT, Strategy and Corporate Finance Report



enquiries@companiesandmarkets.com
www.companiesandmarkets.com/Market/Healthcare-and-Medical/Company-Profile/Recordati-S-p-A-SWOT-Strategy-and-Corporate-Finance-Report/RPT1110292?aCode=e7702a5b-ad88-47dd-bb7a-a58072d4bda2

 

News Alerts

Receive alerts for Companiesandmarkets.com to your inbox. Sign up for News Alerts